A randomized, 8 ‐week, double‐blind, placebo‐controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52‐week open‐label extension trial

ConclusionsVortioxetine failed to meet significance versus placebo in the primary efficacy analysis at week 8 in the short term‐study. The extension trial indicated continued improvement of depressive symptoms from baseline of this study throughout the 52‐week treatment period. Vortioxetine treatment was safe and well tolerated in both studies. Trial RegistrationThe short‐term study has the ClinicalTrials.gov identifier NCT01355081; the open‐label, long‐term extension trial has the ClinicalTrials.gov identifier NCT01395147
Source: Psychiatry and Clinical Neurosciences - Category: Neuroscience Authors: Tags: Regular Article Source Type: research